Clinical, Cytogenetic, and FISH Results of Seven Secondary Leukemia Patients
| Patient No. . | Sex/Age . | Primary Tumor . | Secondary Leukemia . | Therapy* . | Duration (yrs)=d . | Survival Time (mo) . | Monosomy 7 (%) . | Total Cells . | No. of ABL Gene . | ABL Gene Amplification (%) . | CD3 Amplification . | Karyotype . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | . | . | . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | 7 . | . | . | . |
| 1 | F 71 | Uterus | AML M2 | ;gg-Rays | 6.3 | 5 | 89.3 | 183 | 0 | 60 | 87 | 29 | 6 | 1 | 0 | 67.2 | ;ms | 41,XX,;ms5,;ms7,;ms15,;ms20,;ms21,;ms22,;ms22,;pl2r;ob10;cb/41,XX,;ms5.;ms7,;ms11,;ms16,;ms19,;ms20,;ms21,;plmar1, ;plmar2;ob9;cb.nuc ish 9q34(ABLx2-4) |
| 40Gy | ||||||||||||||||||
| CP | ||||||||||||||||||
| 2 | F 67 | Uterus | AML M4 | ;gg-Rays | 5.5 | 8 | 27.4 | 219 | 0 | 210 | 2 | 4 | 3 | 0 | 0 | 4.1 | ;ms | 46,XX;ob20;cb.nuc ish 9q34(ABLx2) |
| 3 | F 70 | Uterus | AML M2 | ;gg-Rays | 9.7 | 17 | 4.6 | 221 | 0 | 213 | 0 | 8 | 0 | 0 | 0 | 3.6 | ;ms | 46,XX;ob22;cb.nuc ish 9q34(ABLx2) |
| 4=D | F 63 | Breast | AML M1 | 5-FU | 7.3 | 2.3 | 5.0 | 272 | 0 | 66 | 83 | 27 | 80 | 14 | 2 | 75.7 | ;pl | 44,XX,dup(1)(q25q44),del(4)(q25q28),del(5) (q13q31),i(11)(q10),der(12)t(11;12)(q23;p12), del(13)(q12q14),;ms14,;ms17,add(19)(q13),der(19) t(?;?11;19)(?;q13;q134);ob27;cb.nuc ish 9q34(ABLx2-5) |
| 5=D | M 69 | Larynx | AML M4 | 5-FU | 2.5 | 2 | 13.2 | 219 | 0 | 210 | 5 | 4 | 0 | 0 | 0 | 4.1 | ;ms | 47,XY,;ms15,add(18)(q23),del(20) (q11q12),;plmar1,;plmar2;ob21;cb.nuc ish 9q34(ABLx2) |
| 6 | M 91 | Skin | ||||||||||||||||
| (melanoma) | ALL L1 | ;gg-Rays | 12.3 | 3 | 30.3 | 205 | 0 | 189 | 5 | 8 | 3 | 0 | 0 | 7.7 | ;ms | 45,XY,;ms7;ob12;cb/46,XY;ob9;cb.nuc ish 9q34(ABLx2) | ||
| 45,30Gy | ||||||||||||||||||
| ACNU | ||||||||||||||||||
| DTIC | ||||||||||||||||||
| 7 | M 57 | Lymphoma | AML M4 | VP-16 | 3.6 | 7 | 81.3 | 122 | 0 | 14 | 65 | 42 | 1 | 0 | 0 | 88.5 | ;ms | 45,XY,del(1)(p22),;pldel(1)(q12)x2,del(3)(p11),;ms5,;ms7, del(12)(p11),;ms16,;ms17,;ms17,;ms20,;plmar1,;plmar2, ;plmar3;ob16;cb.nuc ish 9q34(ABLx3-4) |
| Patient No. . | Sex/Age . | Primary Tumor . | Secondary Leukemia . | Therapy* . | Duration (yrs)=d . | Survival Time (mo) . | Monosomy 7 (%) . | Total Cells . | No. of ABL Gene . | ABL Gene Amplification (%) . | CD3 Amplification . | Karyotype . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | . | . | . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | 7 . | . | . | . |
| 1 | F 71 | Uterus | AML M2 | ;gg-Rays | 6.3 | 5 | 89.3 | 183 | 0 | 60 | 87 | 29 | 6 | 1 | 0 | 67.2 | ;ms | 41,XX,;ms5,;ms7,;ms15,;ms20,;ms21,;ms22,;ms22,;pl2r;ob10;cb/41,XX,;ms5.;ms7,;ms11,;ms16,;ms19,;ms20,;ms21,;plmar1, ;plmar2;ob9;cb.nuc ish 9q34(ABLx2-4) |
| 40Gy | ||||||||||||||||||
| CP | ||||||||||||||||||
| 2 | F 67 | Uterus | AML M4 | ;gg-Rays | 5.5 | 8 | 27.4 | 219 | 0 | 210 | 2 | 4 | 3 | 0 | 0 | 4.1 | ;ms | 46,XX;ob20;cb.nuc ish 9q34(ABLx2) |
| 3 | F 70 | Uterus | AML M2 | ;gg-Rays | 9.7 | 17 | 4.6 | 221 | 0 | 213 | 0 | 8 | 0 | 0 | 0 | 3.6 | ;ms | 46,XX;ob22;cb.nuc ish 9q34(ABLx2) |
| 4=D | F 63 | Breast | AML M1 | 5-FU | 7.3 | 2.3 | 5.0 | 272 | 0 | 66 | 83 | 27 | 80 | 14 | 2 | 75.7 | ;pl | 44,XX,dup(1)(q25q44),del(4)(q25q28),del(5) (q13q31),i(11)(q10),der(12)t(11;12)(q23;p12), del(13)(q12q14),;ms14,;ms17,add(19)(q13),der(19) t(?;?11;19)(?;q13;q134);ob27;cb.nuc ish 9q34(ABLx2-5) |
| 5=D | M 69 | Larynx | AML M4 | 5-FU | 2.5 | 2 | 13.2 | 219 | 0 | 210 | 5 | 4 | 0 | 0 | 0 | 4.1 | ;ms | 47,XY,;ms15,add(18)(q23),del(20) (q11q12),;plmar1,;plmar2;ob21;cb.nuc ish 9q34(ABLx2) |
| 6 | M 91 | Skin | ||||||||||||||||
| (melanoma) | ALL L1 | ;gg-Rays | 12.3 | 3 | 30.3 | 205 | 0 | 189 | 5 | 8 | 3 | 0 | 0 | 7.7 | ;ms | 45,XY,;ms7;ob12;cb/46,XY;ob9;cb.nuc ish 9q34(ABLx2) | ||
| 45,30Gy | ||||||||||||||||||
| ACNU | ||||||||||||||||||
| DTIC | ||||||||||||||||||
| 7 | M 57 | Lymphoma | AML M4 | VP-16 | 3.6 | 7 | 81.3 | 122 | 0 | 14 | 65 | 42 | 1 | 0 | 0 | 88.5 | ;ms | 45,XY,del(1)(p22),;pldel(1)(q12)x2,del(3)(p11),;ms5,;ms7, del(12)(p11),;ms16,;ms17,;ms17,;ms20,;plmar1,;plmar2, ;plmar3;ob16;cb.nuc ish 9q34(ABLx3-4) |
Therapy for the primary tumors: CP, cyclophosphamide; 5-FU, 5-fluorouracil; ACNU, nimustine; DTIC, dacarbazine; VP-16, etoposide.
=d Interval from last therapy till diagnosis of secondary leukemia.
=D Hiroshima A-bomb survivors.